Upregulation of Id3 inhibits cell proliferation and induces apoptosis in A549/DDP human lung cancer cells in vitro

Chen,Fangfang; Zhao,Qinfei; Wang,Shuxia; Wang,Haiyong; Li,Xiaojun

doi:10.3892/mmr.2016.5221

Upregulation of Id3 inhibits cell proliferation and induces apoptosis in A549/DDP human lung cancer cells in vitro

Authors:
- Fangfang Chen
- Qinfei Zhao
- Shuxia Wang
- Haiyong Wang
- Xiaojun Li
View Affiliations

Affiliations: Center of Clinical Laboratory Science, Jinling Hospital, School of Medicine, Southern Medical University, Nanjing, Jiangsu 210002, P.R. China
Published online on: May 9, 2016 https://doi.org/10.3892/mmr.2016.5221
Pages: 313-318

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Inhibitor of DNA binding (Id)3 is a member of the Id multigene family of dominant‑negative helix‑loop-helix transcription factors, which function as oncogenes or tumor suppressors in human cancers. Its upregulation was recently shown to have inhibitory effects on lung cancer, which is the leading cause of cancer‑associated mortality worldwide. As drug resistance represents a major bottleneck of cancer therapy, the present study assessed the ability of Id3 to inhibit cisplatin‑resistant A549 lung adenocarcinoma cells (A549/DDP). A549/DPP cells were transiently transfected with enhanced green fluorescence protein overexpression plasmid (pEGFP) or Id3 overexpression plasmid (Id3/pEGFP), which was confirmed by confocal fluorescence microscopy, PCR and western blot analysis. The effects of Id3 on the viability and apoptosis of A549/DDP were determined using an MTT assay, fluorescence microscopy with Hoechst 33258 staining and flow cytometry following Annexin V/propidium iodide double staining. The results revealed that overexpression of Id3 significantly inhibited the proliferation and viability of A549/DDP cells in a time‑dependent manner. Furthermore, overexpression of Id3 significantly increased the apoptotic rate of A549/DDP cells from 2.73 to 16.92%, confirming the implication of Id3 in the negative control of tumour growth. The results of the present study revealed that overexpression of Id3 may serve as a novel strategy for inhibiting cisplatin‑sensitive lung cancer. Further experiments will be performed to determine whether Id3 overexpression could enhance the sensitivity of lung cancer cells to DDP.

View Figures

View References

1	Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG and Shepherd FA: Non-small-cell lung cancer. Lancet. 378:1727–1740. 2011. View Article : Google Scholar : PubMed/NCBI
2	Benezra R, Davis RL, Lockshon D, Turner DL and Weintraub H: The protein Id: A negative regulator of helix-loop-helix DNA binding proteins. Cell. 61:49–59. 1990. View Article : Google Scholar : PubMed/NCBI
3	Finkel T, Duc J, Fearon ER, Dang CV and Tomaselli GF: Detection and modulation in vivo of helix-loop-helix protein-protein interactions. J Biol Chem. 268:5–8. 1993.PubMed/NCBI
4	Lasorella A, Uo T and Iavarone A: Id proteins at the cross-road of development and cancer. Oncogene. 20:8326–8333. 2001. View Article : Google Scholar
5	Ruzinova MB and Benezra R: Id proteins in development, cell cycle and cancer. Trends Cell Biol. 13:410–418. 2003. View Article : Google Scholar : PubMed/NCBI
6	Rotzer D, Krampert M, Sulyok S, Braun S, Stark HJ, Boukamp P and Werner S: Id proteins: Novel targets of activin action, which regulate epidermal homeostasis. Oncogene. 25:2070–2081. 2006. View Article : Google Scholar
7	Li XJ, Hata K and Mizuguchi J: Engagement of membrane immunoglobulin enhances Id3 promoter activity in WEHI-231 B lymphoma cells. Acta Pharmacol Sin. 26:486–491. 2005. View Article : Google Scholar : PubMed/NCBI
8	Lee KT, Lee YW, Lee JK, Choi SH, Rhee JC, Paik SS and Kong G: Overexpression of Id-1 is significantly associated with tumour angiogenesis in human pancreas cancers. Br J Cancer. 90:1198–1203. 2004. View Article : Google Scholar : PubMed/NCBI
9	Peng Y, Kang Q, Luo Q, Jiang W, Si W, Liu BA, Luu HH, Park JK, Li X, Luo J, et al: Inhibitor of DNA binding/differentiation helix-loop-helix proteins mediate bone morphogenetic protein-induced osteoblast differentiation of mesenchymal stem cells. J Biol Chem. 279:32941–32949. 2004. View Article : Google Scholar : PubMed/NCBI
10	Kee BL, Rivera RR and Murre C: Id3 inhibits B lymphocyte progenitor growth and survival in response to TGF-beta. Nat Immunol. 2:242–247. 2001. View Article : Google Scholar : PubMed/NCBI
11	Simbulan-Rosenthal CM, Daher A, Trabosh V, Chen WC, Gerstel D, Soeda E and Rosenthal DS: Id3 induces a caspase-3- and -9-dependent apoptosis and mediates UVB sensitization of HPV16 E6/7 immortalized human keratinocytes. Oncogene. 25:3649–3660. 2006. View Article : Google Scholar : PubMed/NCBI
12	Koyama T, Suzuki H, Imakiire A, Yanase N, Hata K and Mizuguchi J: Id3-mediated enhancement of cisplatin-induced apoptosis in a sarcoma cell line MG-63. Anticancer Res. 24:1519–1524. 2004.PubMed/NCBI
13	Li XJ, Zhu CD, Yu W, Wang P, Chen FF, Xia XY and Luo B: Overexpression of Id3 induces apoptosis of A549 human lung adenocarcinoma cells. Cell Prolif. 45:1–8. 2012. View Article : Google Scholar
14	Chen FF, Liu Y, Wang F, et al: Effects of upregulation of Id3 in human lung adenocarcinoma cells on proliferation, apoptosis, mobility and tumorigenicity. Cancer Gene Therapy. 22:431–437. 2015. View Article : Google Scholar : PubMed/NCBI
15	Fridman E, Skarda J, Pinthus JH, Ramon J and Mor Y: Expression of multidrug resistance-related protein (MRP-1), lung resistance-related protein (LRP) and topoisomerase-II (TOPO-II) in Wilms' tumor: Immunohistochemical study using TMA methodology. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 152:47–51. 2008. View Article : Google Scholar : PubMed/NCBI
16	Asnaghi L, Calastretti A, Bevilacqua A, D'Agnano I, Gatti G, Canti G, Delia D, Capaccioli S and Nicolin A: Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by Akt. Oncogene. 23:5781–5791. 2004. View Article : Google Scholar : PubMed/NCBI
17	Scagliotti GV, Novello S and Selvaggi G: Multidrug resistance in non-small-cell lung cancer. Ann Oncol. 10(Suppl 5): S83–S86. 1999. View Article : Google Scholar : PubMed/NCBI
18	Takara K, Sakaeda T and Okumura K: An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des. 12:273–286. 2006. View Article : Google Scholar : PubMed/NCBI
19	Damdinsuren B, Nagano H, Kondo M, Yamamoto H, Hiraoka N, Yamamoto T, Marubashi S, Miyamoto A, Umeshita K, Dono K, et al: Expression of Id proteins in human hepatocellular carcinoma: Relevance to tumor dedifferentiation. Int J Oncol. 26:319–321. 2005.PubMed/NCBI
20	Asirvatham AJ, Carey JP and Chaudhary J: ID1-, ID2- and ID3-regulated gene expression in E2A positive or negative prostate cancer cells. Prostate. 67:1411–1420. 2007. View Article : Google Scholar : PubMed/NCBI
21	Arnold JM, Mok SC, Purdie D and Chenevix-Trench G: Decreased expression of the Id3 gene at 1p36.1 in ovarian adenocarcinomas. Br J Cancer. 84:352–359. 2001. View Article : Google Scholar : PubMed/NCBI
22	Moon C, Oh Y and Roth JA: Current status of gene therapy for lung cancer and head and neck cancer. Clin Cancer Res. 9:5055–5067. 2003.PubMed/NCBI
23	Wilson JW, Deed RW, Inoue T, Balzi M, Becciolini A, Faraoni P, Potten CS and Norton JD: Expression of Id helix-loop-helix proteins in colorectal adenocarcinoma correlates with p53 expression and mitotic index. Cancer Res. 61:8803–8810. 2001.PubMed/NCBI
24	Rockman SP, Currie SA, Ciavarella M, Vincan E, Dow C, Thomas RJ and Phillips WA: Id2 is a target of the beta-catenin/T cell factor pathway in colon carcinoma. J Biol Chem. 276:45113–45119. 2001. View Article : Google Scholar : PubMed/NCBI
25	Lee SH, Hao E, Kiselyuk A, Shapiro J, Shields DJ, Lowy A, Levine F and Itkin-Ansari P: The Id3/E47 axis mediates cell-cycle control in human pancreatic ducts and adenocarcinoma. Mol Cancer Res. 9:782–790. 2011. View Article : Google Scholar : PubMed/NCBI
26	Kamalian L, Forootan SS, Bao ZZ, Zhang Y, Gosney JR, Foster CS and Ke Y: Inhibition of tumourigenicity of small cell lung cancer cells by suppressing Id3 expression. Int J Oncol. 37:595–603. 2010.PubMed/NCBI
27	Pucci B, Kasten M and Giordano A: Cell cycle and apoptosis. Neoplasia. 2:291–299. 2000. View Article : Google Scholar : PubMed/NCBI
28	Hu MD, Xu JC, Fan Y, Xie QC, Li Q, Zhou CX, Mao M and Yang Y: Hypoxia-inducible factor 1 promoter-induced JAB1 overexpression enhances chemotherapeutic sensitivity of lung cancer cell line A549 in an anoxic environment. Asian Pac J Cancer Prev. 13:2115–2120. 2012. View Article : Google Scholar : PubMed/NCBI
29	Yu HG, Wei W, Xia LH, Han WL, Zhao P, Wu SJ, Li WD and Chen W: FBW7 upregulation enhances cisplatin cytotoxicity in non-small cell lung cancer cells. Asian Pac J Cancer Prev. 14:6321–6326. 2013. View Article : Google Scholar
30	Langenfeld E, Deen M, Zachariah E and Langenfeld J: Small molecule antagonist of the bone morphogenetic protein type I receptors suppresses growth and expression of Id1 and Id3 in lung cancer cells expressing Oct4 or nestin. Mol Cancer. 12:1292013. View Article : Google Scholar : PubMed/NCBI
31	Langenfeld E, Hong CC, Lanke G and Langenfeld J: Bone morphogenetic protein type I receptor antagonists decrease growth and induce cell death of lung cancer cell lines. PLoS One. 8:e612562013. View Article : Google Scholar : PubMed/NCBI
32	Chen D, Forootan SS, Gosney JR, Forootan FS and Ke Y: Increased expression of Id1 and Id3 promotes tumorigenicity by enhancing angiogenesis and suppressing apoptosis in small cell lung cancer. Genes Cancer. 5:212–225. 2014.PubMed/NCBI
33	Castañon E, Bosch-Barrera J, López I, Collado V, Moreno M, López-Picazo JM, Arbea L, Lozano MD, Calvo A and Gil-Bazo I: Id1 and Id3 co-expression correlates with clinical outcome in stage III-N2 non-small cell lung cancer patients treated with definitive chemoradiotherapy. J Transl Med. 11:132013. View Article : Google Scholar : PubMed/NCBI